checkAd

DGAP-News Xlife Sciences AG (XLS): Joint venture with anfass Life Technologies

Nachrichtenquelle: EQS Group AG
05.03.2021, 07:30  |  143   |   |   

DGAP-News: Xlife Sciences AG / Key word(s): Merger
Xlife Sciences AG (XLS): Joint venture with anfass Life Technologies

05.03.2021 / 07:30
The issuer is solely responsible for the content of this announcement.


Xlife Sciences AG (XLS): Joint venture with anfass Life Technologies

Development of highly effective antibodies without animal testing

Xlife Sciences AG and Solothurn-based anfass Life Technologies AG have entered a joint venture. Hence, the jointly founded Quadira Biosciences AG has access to the 3D CoSeedis(TM) technology platform of abc biopply ag. This unique 3D cell technology enables the replication of human tissue for reliable testing and characterization of antibodies without animal testing. Xlife's technology platform for the development of antibodies will be used even more efficiently.

As of today, Xlife Sciences AG has already identified 30 compounds with blockbuster potential with its antibody screening platform. These therapeutic antibodies have already shown to be safe and effective in humans. Xlife can modify these antibodies with utmost accuracy and increase the quality of the active ingredient. These are mainly advanced, highly potent antibodies with higher cytotoxic activity and improved side effect profile for cancer therapy. The target market potential of the pre-selected antibodies is in the range of several billion US dollars.

With the collaboration of abc biopply, a portfolio company of anfass Life Technologies, the development process will be advanced significantly. Abc biopply developed a technology platform 3D CoSeedis(TM) that allows the testing and characterization in terms of efficacy of antibodies in 3D- cell cultures, also known as organoids, which are similar to animal or human tissue. This reduces or even eliminates animal testing and accelerates product development significantly. 3D CoSeedis(TM) differentiates itself with its unique homogeneity of produced spheroids and allows standardized mass production. This leads to simplified preclinical modelling of diseases. With this sustainable joint-venture, Quadira Biosciences AG could revolutionize cancer therapy.

Seite 1 von 3
Xlife Sciences Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen

Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

DGAP-News Xlife Sciences AG (XLS): Joint venture with anfass Life Technologies DGAP-News: Xlife Sciences AG / Key word(s): Merger Xlife Sciences AG (XLS): Joint venture with anfass Life Technologies 05.03.2021 / 07:30 The issuer is solely responsible for the content of this announcement. Xlife Sciences AG (XLS): Joint …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel

COMMUNITY

ZeitTitel
18.02.21